UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia

Respiratory medicine, 2024-04, Vol.229, p.107611-107611, Article 107611

2024

Volltextzugriff (PDF)

Technical Note: Single time point dose estimate for exponential clearance

Medical physics (Lancaster), 2018-05, Vol.45 (5), p.2318-2324

2018

Volltextzugriff (PDF)

Addition of 131 I-MIBG to PRRT ( 90 Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Journal of Nuclear Medicine, 2021-09, Vol.62 (9), p.1274-1277

2021

Volltextzugriff (PDF)

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

The Journal of nuclear medicine (1978), 2021-09, Vol.62 (9), p.1274-1277

2021

Volltextzugriff (PDF)

Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors

Pancreas, 2013-08, Vol.42 (6), p.937-943

2013

Volltextzugriff (PDF)

90 Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine, 2018-11, Vol.59 (11), p.1692-1698

2018

Volltextzugriff (PDF)

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

The Journal of nuclear medicine (1978), 2018-11, Vol.59 (11), p.1692-1698

2018

Volltextzugriff (PDF)

Potential for Increasing Uptake of Radiolabeled 68 Ga-DOTATOC and 123 I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat

Cancer biotherapy & radiopharmaceuticals, 2021-10, Vol.36 (8), p.632-641

2021

Volltextzugriff (PDF)

sup 90^Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy

The Journal of nuclear medicine (1978), 2018-11, Vol.59 (11), p.1692

2018

Volltextzugriff (PDF)

The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process

Pancreas, 2010-08, Vol.39 (6), p.705-706

2010

Volltextzugriff (PDF)

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

EJNMMI research, 2014-12, Vol.4 (1), p.38-38

2014

Volltextzugriff (PDF)

Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging

Clinical cancer research, 2004-05, Vol.10 (9), p.2997-3006

2004

Volltextzugriff (PDF)

Dosimetric advantage of combining 131I-MIBG and 90Y-DOTATOC

Regulatory peptides, 2010-09, Vol.164 (1), p.11-11

2010

Volltextzugriff (PDF)

Phase I Trial of 90 Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

Journal of Nuclear Medicine, 2010-10, Vol.51 (10), p.1524-1531

2010

Volltextzugriff (PDF)

Phase I Trial of ^sup 90^Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

The Journal of nuclear medicine (1978), 2010-10, Vol.51 (10), p.1524

2010

Volltextzugriff (PDF)

Phase I Trial of 90Y-DOTA0-Tyr3-Octreotide Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

The Journal of nuclear medicine (1978), 2010-09, Vol.51 (10), p.1524-1531

2010

Volltextzugriff (PDF)

Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

EJNMMI research, 2014-09, Vol.4 (1), Article 38

2014

Volltextzugriff (PDF)

Phase I Trial of 90Y-DOTA-tyr 3-Octreotide in Children and Young Adults

Pancreas, 2010-03, Vol.39 (2), p.278-279

2010

Volltextzugriff (PDF)

Potential Increased Tumor-Dose Delivery with Combined 131I-MIBG and 90Y-DOTATOC Treatment in Neuroendocrine Tumors: A Theoretic Model

The Journal of nuclear medicine (1978), 2006-04, Vol.47 (4), p.660

2006

Volltextzugriff (PDF)

Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)

Endocrine Abstracts, 2023-02

2023

Volltextzugriff (PDF)

Multiple endocrine neoplasia type 2A: A 25-year review

Journal of pediatric surgery, 1999, Vol.34 (1), p.92-97

1999

Volltextzugriff (PDF)

Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors

The Journal of nuclear medicine (1978), 2010-10, Vol.51 (10), p.1524

2010

Volltextzugriff (PDF)

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment

Cancer biotherapy & radiopharmaceuticals, 2004-02, Vol.19 (1), p.35-41

2004

Volltextzugriff (PDF)

The differential effects of body fat distribution on insulin and glucose metabolism during pregnancy

American journal of obstetrics and gynecology, 1994-10, Vol.171 (4), p.875-884

1994

Volltextzugriff (PDF)

PET/CT based dosimetry for 90Y-DOTATOC treatment of neuroendocrine cancer

Endocrine Abstracts, 2016-11

2016

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Female
(10)
Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Adult
(7)
Male
(7)
Octreotide - Analogs & Derivatives
(7)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Middle Aged
(5)
Octreotide - Therapeutic Use
(4)
Radiopharmaceuticals - Therapeutic Use
(4)
Tumors
(4)
Aged
(3)
Amino Acids
(3)
Bone Marrow
(3)
Child
(3)
Child, Preschool
(3)
Neuroendocrine Tumors
(3)
Neuroendocrine Tumors - Diagnosis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia

Technical Note: Single time point dose estimate for exponential clearance

Addition of 131 I-MIBG to PRRT ( 90 Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors

90 Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy

Potential for Increasing Uptake of Radiolabeled 68 Ga-DOTATOC and 123 I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat

sup 90^Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy

The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging

Dosimetric advantage of combining 131I-MIBG and 90Y-DOTATOC

Phase I Trial of 90 Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

Phase I Trial of ^sup 90^Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

Phase I Trial of 90Y-DOTA0-Tyr3-Octreotide Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors

Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

Phase I Trial of 90Y-DOTA-tyr 3-Octreotide in Children and Young Adults

Potential Increased Tumor-Dose Delivery with Combined 131I-MIBG and 90Y-DOTATOC Treatment in Neuroendocrine Tumors: A Theoretic Model

Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)

Multiple endocrine neoplasia type 2A: A 25-year review

Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment

The differential effects of body fat distribution on insulin and glucose metabolism during pregnancy

PET/CT based dosimetry for 90Y-DOTATOC treatment of neuroendocrine cancer

Suchergebnisse filtern